Daisy Genomics
Daisy Genomics is developing a direct optical long-read sequencing platform that detects epigenetic modifications and genomic data inaccessible to current commercial technologies. The platform combines nanochannel fluidics with surface-enhanced Raman spectroscopy (SERS) to sequence native, unamplified DNA molecules at single-base resolution, enabling direct measurement of chemical modifications without labels or library preparation.
- Biotechnology
- Hardware
- Artificial Intelligence
Funding
Founders
Founder details are not available yet.
Product
Problem
Current genomic analysis methods often miss critical epigenetic data and important genomic markers, leading to significant diagnostic gaps. Existing next-generation sequencing approaches require DNA amplification and labeling, cannot directly measure epigenetic modifications, and struggle to resolve large structural variants, leaving many disease-relevant genomic regions unseen.
Solution
Daisy Genomics provides a direct optical long-read sequencing platform that sequences native, unamplified nucleic acid molecules at single-base resolution. DNA is loaded onto proprietary nanochannel structures, linearized, and moved past metamaterial/plasmonic enhancement structures where surface-enhanced Raman spectroscopy (SERS) captures a complete spectral fingerprint of each nucleotide, including epigenetic and chemical modifications. This approach requires no amplification, labels, or library preparation and reads sequences in real time, enabling direct assessment of DNA modifications that other technologies cannot detect. The platform supports long-read applications including structural variant detection, haplotype-resolved sequencing, and de novo whole genome assembly.
Target Audience
Primary customers are genomics researchers, diagnostics companies, and drug development organizations focused on precision medicine, epigenetic disease mechanisms, and applications requiring long-read sequencing of native DNA.
Features
- Direct detection of single nucleotides using non-resonant SERS with metamaterial/plasmonic nanostructures, providing structural information rather than ionic sensing
- Proprietary nanochannel structures approximately 40nm wide that linearize DNA and integrate enhancement structures with electric-field-controlled velocity
- No DNA amplification, labeling, or library preparation required; sequences native molecules in real-time
- Direct measurement of epigenetic modifications with distinct spectra, including examples such as dCTP, 5m-dCT, and 5hm-dCTP
- Ultra-long read capability supporting structural variant detection, haplotype-resolved sequencing, and de novo genome assembly
- Machine-learning-based data analysis integrated into the research and technology platform